Ascidian Therapeutics, founded with a mission to revolutionize gene therapy, focuses on RNA-based treatments to address diseases that current technologies cannot effectively manage. Inspired by the natural RNA re-engineering capabilities of sea squirts, Ascidian aims to unlock new therapeutic possibilities and provide treatments for millions of patients worldwide. The company specializes in RNA exon editing therapeutics, particularly targeting neurological diseases.
Notable affiliations include a collaboration with Roche for the discovery and development of these RNA-based therapies. Ascidian's pioneering approach has positioned it as a significant player in the gene therapy landscape, contributing to advancements in treating previously intractable conditions. The company's innovative methodologies and strategic partnerships underscore its impact on the future of medical treatments.
